Glykochenodesoxycholsaeure | 640-79-9

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Glykochenodesoxycholsaeure
• 英文别名: 3α.7α-Dihydroxy-5β-cholamyl-glycinat；2-[4-[(3R,5S,7R,10S,13R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]acetic acid
• CAS: 640-79-9；13164-20-0；64480-66-6；66255-07-0；93861-57-5；93861-58-6；130008-98-9；132437-62-8；139894-85-2
• 化学式: C₂₆H₄₃NO₅
• 分子量: 449.631
• InChiKey: GHCZAUBVMUEKKP-DEZIUZKFSA-N

物化性质

• 沸点：
  655.6±40.0 °C(Predicted)
• 密度：
  1.162±0.06 g/cm3(Predicted)
• 溶解度：
  二甲基亚砜：≥29mg/mL（64.50mM）

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  107
• 氢给体数：
  4
• 氢受体数：
  5

制备方法与用途

生物活性 Glycochenodeoxycholic acid（甘氧胆酸，胆烷基甘氨酸，甘氨酸鹅去氧胆酸盐）是由肝脏中鹅去氧胆酸盐与甘氨酸结合形成的胆汁盐。它作为一种去垢剂，能够溶解脂肪，从而促进吸收。

靶点 Human Endogenous Metabolite（人类内源性代谢物）

文献信息

• LIPID, PROTEIN, AND METABOLITE MARKERS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
  申请人：Berg LLC

  公开号：EP3490677A1

  公开（公告）日：2019-06-05
• COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS
  申请人：Uysal Teoman

  公开号：US20090131384A1

  公开（公告）日：2009-05-21

  The invention provides novel compounds, methods for treating or preventing a condition related to ER-stress, e.g. hypercholesterolemia, atherosclerosis and related conditions, and pharmaceutical compositions related thereto.
• Metabolomics-Based Identification of Disease-Causing Agents
  申请人：Skolnick Jeffrey

  公开号：US20110246081A1

  公开（公告）日：2011-10-06

  A method, computer-readable medium, and system for identifying one or more metabolites associated with a disease, comprising: comparing gene expression data from diseased cells to gene expression data from control cells in order to deduce genes that are differentially-regulated in the diseased cells relative to the control cells; based on enzyme function and pathway data for all human metabolites that utilize the genes that are differentially-regulated in the disease cells, identifying one or more metabolites whose intracellular levels are higher or lower in diseased cells than in control cells, and thereby associating the one or more metabolites with the disease.
• Metabolic biomarkers of Crohn's Disease
  申请人：Jansson Janet R.

  公开号：US20120213772A1

  公开（公告）日：2012-08-23

  The invention provides for a method for identifying a biomarker in a fecal sample of a subject in need of such identification comprising: determining whether a fecal sample collected from a subject comprises a biomarker.
• METABOLIC BIOMARKERS OF CROHN'S DISEASE
  申请人：The Regents of the University of California

  公开号：US20180203018A1

  公开（公告）日：2018-07-19

  The invention provides for a method for identifying a biomarker in a fecal sample of a subject in need of such identification comprising: determining whether a fecal sample collected from a subject comprises a biomarker.